People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other Health Care, Medical Devices, Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moximed, Inc | — | Other Health Care | Series C | $187.8M | $499.3M | 2009 |
| ExploraMed NC7, Inc. | — | Other Health Care | Series C | $181.5M | $751.6M | 2017 |
| Minerva Surgical Inc | — | Medical Devices | Series B | $167.3M | $397.4M | 2016 |
| Neotract Inc | — | Other Health Care | Series C | $117.5M | $293.0M | 2009 |
| Derivative Path Inc | — | Other Technology | Series B | $35.0M | $1.1B | 2020 |
| Stimwave Technologies Inc | — | Biotechnology | Seed | $9.8M | $132.9M | 2013 |
Robert K. Anderson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert K. Anderson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ryan Drant | 3 | 24 |
| Robert Anderson | 3 | 24 |
| John Nehra | 3 | 11 |
| Joshua Makower | 3 | 10 |
| Robert W. Croce | 3 | 7 |
| Joshua W. Makower | 3 | 4 |
| ROBERT CROCE | 2 | 7 |
| David Amerson | 2 | 5 |
| Ryan W. Drant | 2 | 4 |
| Christopher Gleason | 1 | 35 |
| Ali Behbahani | 1 | 17 |
| PAUL LAVIOLETTE | 1 | 12 |
| Albert Cha | 1 | 9 |
| Csaba Truckai | 1 | 7 |
| Ross Jaffe | 1 | 7 |
| Henry A. Plain, Jr. | 1 | 7 |
| Michael Carusi | 1 | 7 |
| Rodney Perkins | 1 | 6 |
| JEFFREY GOLDBERG | 1 | 6 |
| David Clapper | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.